Abstract
Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Current Signal Transduction Therapy
Title: Hepatocyte Growth Factor Signaling in Cancer Metastasis
Volume: 6 Issue: 2
Author(s): Tracey A. Martin, Malcolm D. Mason and Wen G. Jiang
Affiliation:
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Abstract: Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Export Options
About this article
Cite this article as:
A. Martin Tracey, D. Mason Malcolm and G. Jiang Wen, Hepatocyte Growth Factor Signaling in Cancer Metastasis, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795659991
DOI https://dx.doi.org/10.2174/157436211795659991 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry MicroRNA: The Potential Regulator of Endometrial Carcinogenesis
MicroRNA Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Reproductive Toxicology of Environmental Toxicants: Emerging Issues and Concerns
Current Pharmaceutical Design MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]
Combinatorial Chemistry & High Throughput Screening PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Patent Selections
Recent Patents on Regenerative Medicine Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science An Overview on Fibroblast Growth Factors: Structural, Functional and Therapeutic Implications
Current Proteomics Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry